Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been assigned an average recommendation of “Buy” from the eight research firms that are presently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $6.63.
Several research analysts have commented on the company. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, February 27th.
Get Our Latest Research Report on TSHA
Taysha Gene Therapies Stock Performance
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The company had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. On average, research analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current year.
Institutional Trading of Taysha Gene Therapies
A number of institutional investors have recently modified their holdings of the business. Hsbc Holdings PLC boosted its stake in shares of Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock valued at $36,000 after buying an additional 8,076 shares in the last quarter. Virtus ETF Advisers LLC boosted its position in Taysha Gene Therapies by 43.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company’s stock worth $55,000 after purchasing an additional 9,494 shares in the last quarter. Geode Capital Management LLC boosted its position in Taysha Gene Therapies by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock worth $6,182,000 after purchasing an additional 9,591 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Taysha Gene Therapies by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock worth $820,000 after purchasing an additional 11,390 shares in the last quarter. Finally, Creative Planning purchased a new stake in Taysha Gene Therapies during the third quarter worth $28,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.
Taysha Gene Therapies Company Profile
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Featured Articles
- Five stocks we like better than Taysha Gene Therapies
- What Are Dividend Achievers? An Introduction
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is a Secondary Public Offering? What Investors Need to Know
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- 3 REITs to Buy and Hold for the Long Term
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.